eGenesis

eGenesis is a clinical-stage biotech developing human-compatible organs from genetically engineered pigs to solve the critical shortage of donor organs. The company's platform utilizes multiplex CRISPR-based gene editing to inactivate endogenous retroviruses, knock out immunogenic antigens, and insert human protective genes. With an FDA-cleared IND for its lead kidney program (EGEN-2784) now in a Phase 1/2/3 trial and a second IND for a liver program (EGEN-5784), eGenesis is a leader in advancing xenotransplantation from concept to clinical reality. The company is privately held and backed by prominent life science investors.

Integrated xenotransplantation platform utilizing multiplex CRISPR gene editing for three classes of modifications: endogenous retrovirus inactivation (RI), triple glycan antigen knockout (TKO), and insertion of human transgenes to regulate immune response, coagulation, and inflammation. Combined with cloning and pathogen-free donor pig production.

eGenesis competes in a nascent but active field of xenotransplantation. Key competitors include United Therapeutics (via its Revivicor subsidiary, which supplied the pig for the first FDA-authorized heart xenotransplant) and other biotechs like Makana Therapeutics. Large pharmaceutical companies may enter through partnerships or acquisitions. eGenesis differentiates itself with its comprehensive, multi-edit genetic platform designed for long-term compatibility.